Genome-wide expression profile of human melanoma patient derived xenograft (PDX) tumors that were treated with ARN22089 at 0 (vehicle), 10 mg/kg and 25 mg/kg IV in NSG mice (NOD.Cg-Prkdcscid IL2rgtm1Wjl/SzJ). Genome-wide expression profile of human melanoma patient derived xenograft (PDX) tumors that were treated with ARN22089 at 0 (vehicle), 10 mg/kg and 25 mg/kg IV in NSG mice (NOD.Cg-Prkdcscid IL2rgtm1Wjl/SzJ)

To determine the long-term ARN22089 treatment on tumor growth Overall design: Inoculated mice with one BRAF mutant PDX that was known to have consistent growth properties. Mice were treated with ARN22089 with 0, 10 mg/kg, or 25 mg/kg IV BIW until control tumors reached endpoint.